Because of the sex-gender differences that are shown in a diversity of physiological and psychological factors, it can be speculated that the clinical presentation of symptoms as well as treatment strategies in women and men with irritable bowel syndrome IBS may differ. Studies have revealed that IBS is more common in women than men.
Sex hormones and gender differences may play important roles in the pathophysiology of IBS. However, its pathophysiologic mechanisms still remain largely unknown, and therapeutic implications are limited.
Moreover, women IBS patients have been reported to feel more fatigue, depression, anxiety, and lower quality of life than men IBS patients. Furthermore, there has been evidence of differences in the appropriate treatment efficacy to IBS in men and women, although relatively few men are enrolled in most relevant clinical trials. A more sex-gender-oriented approach in the medical care setting could improve understanding of heterogeneous patients suffering from IBS. An individualized and multicomponent approach including sex and gender issues might help improve the treatment of IBS.
Irritable bowel syndrome IBS is one of the most common functional gastrointestinal disorders FGID , defined by abdominal pain and abnormal bowel habits with no detectable organic disease.
Interestingly, most FGIDs in general show female predominance. Sex means biological distinctions characterizing males and females, whereas gender reflects sex-related social roles with which an individual identifies, and that presumably reflect learned femininity or masculinity. Gender is assumed to be a crucial factor in the pathogenesis, disease progression, and even prognosis of various diseases. Even though IBS is more common in women, the underlying mechanism by which women exhibit an increased vulnerability to IBS remains largely unknown, and therapeutic treatments are also limited.
